Cargando…

Inhibitor Design Strategy for Myostatin: Dynamics and Interaction Networks Define the Affinity and Release Mechanisms of the Inhibited Complexes

Myostatin, an important negative regulator of muscle mass, is a therapeutic target for muscle atrophic disorders such as muscular dystrophy. Thus, the inhibition of myostatin presents a strategy to treat these disorders. It has long been established that the myostatin prodomain is a strong inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagy-Fazekas, Dóra, Fazekas, Zsolt, Taricska, Nóra, Stráner, Pál, Karancsiné Menyhárd, Dóra, Perczel, András
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10420283/
https://www.ncbi.nlm.nih.gov/pubmed/37570625
http://dx.doi.org/10.3390/molecules28155655
_version_ 1785088740543168512
author Nagy-Fazekas, Dóra
Fazekas, Zsolt
Taricska, Nóra
Stráner, Pál
Karancsiné Menyhárd, Dóra
Perczel, András
author_facet Nagy-Fazekas, Dóra
Fazekas, Zsolt
Taricska, Nóra
Stráner, Pál
Karancsiné Menyhárd, Dóra
Perczel, András
author_sort Nagy-Fazekas, Dóra
collection PubMed
description Myostatin, an important negative regulator of muscle mass, is a therapeutic target for muscle atrophic disorders such as muscular dystrophy. Thus, the inhibition of myostatin presents a strategy to treat these disorders. It has long been established that the myostatin prodomain is a strong inhibitor of the mature myostatin, and the minimum peptide of the prodomain—corresponding to the α(1)-helix of its lasso-region—responsible for the inhibitory efficiency was defined and characterized as well. Here we show that the minimum peptide segment based on the growth differentiation factor 11 (GDF11), which we found to be more helical in its stand-alone solvated stfate than the similar segment of myostatin, is a promising new base scaffold for inhibitor design. The proposed inhibitory peptides in their solvated state and in complex with the mature myostatin were analyzed by in silico molecule modeling supplemented with the electronic circular dichroism spectroscopy measurements. We defined the Gaussian–Mahalanobis mean score to measure the fraction of dihedral angle-pairs close to the desired helical region of the Ramachandran-plot, carried out RING analysis of the peptide-protein interaction networks and characterized the internal motions of the complexes using our rigid-body segmentation protocol. We identified a variant—11m2—that is sufficiently ordered both in solvent and within the inhibitory complex, forms a high number of contacts with the binding-pocket and induces such changes in its internal dynamics that lead to a rigidified, permanently locked conformation that traps this peptide in the binding site. We also showed that the naturally evolved α(1)-helix has been optimized to simultaneously fulfill two very different roles: to function as a strong binder as well as a good leaving group. It forms an outstanding number of non-covalent interactions with the mature core of myostatin and maintains the most ordered conformation within the complex, while it induces independent movement of the gate-keeper β-hairpin segment assisting the dissociation and also results in the least-ordered solvated form which provides extra stability for the dissociated state and discourages rebinding.
format Online
Article
Text
id pubmed-10420283
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104202832023-08-12 Inhibitor Design Strategy for Myostatin: Dynamics and Interaction Networks Define the Affinity and Release Mechanisms of the Inhibited Complexes Nagy-Fazekas, Dóra Fazekas, Zsolt Taricska, Nóra Stráner, Pál Karancsiné Menyhárd, Dóra Perczel, András Molecules Article Myostatin, an important negative regulator of muscle mass, is a therapeutic target for muscle atrophic disorders such as muscular dystrophy. Thus, the inhibition of myostatin presents a strategy to treat these disorders. It has long been established that the myostatin prodomain is a strong inhibitor of the mature myostatin, and the minimum peptide of the prodomain—corresponding to the α(1)-helix of its lasso-region—responsible for the inhibitory efficiency was defined and characterized as well. Here we show that the minimum peptide segment based on the growth differentiation factor 11 (GDF11), which we found to be more helical in its stand-alone solvated stfate than the similar segment of myostatin, is a promising new base scaffold for inhibitor design. The proposed inhibitory peptides in their solvated state and in complex with the mature myostatin were analyzed by in silico molecule modeling supplemented with the electronic circular dichroism spectroscopy measurements. We defined the Gaussian–Mahalanobis mean score to measure the fraction of dihedral angle-pairs close to the desired helical region of the Ramachandran-plot, carried out RING analysis of the peptide-protein interaction networks and characterized the internal motions of the complexes using our rigid-body segmentation protocol. We identified a variant—11m2—that is sufficiently ordered both in solvent and within the inhibitory complex, forms a high number of contacts with the binding-pocket and induces such changes in its internal dynamics that lead to a rigidified, permanently locked conformation that traps this peptide in the binding site. We also showed that the naturally evolved α(1)-helix has been optimized to simultaneously fulfill two very different roles: to function as a strong binder as well as a good leaving group. It forms an outstanding number of non-covalent interactions with the mature core of myostatin and maintains the most ordered conformation within the complex, while it induces independent movement of the gate-keeper β-hairpin segment assisting the dissociation and also results in the least-ordered solvated form which provides extra stability for the dissociated state and discourages rebinding. MDPI 2023-07-26 /pmc/articles/PMC10420283/ /pubmed/37570625 http://dx.doi.org/10.3390/molecules28155655 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Nagy-Fazekas, Dóra
Fazekas, Zsolt
Taricska, Nóra
Stráner, Pál
Karancsiné Menyhárd, Dóra
Perczel, András
Inhibitor Design Strategy for Myostatin: Dynamics and Interaction Networks Define the Affinity and Release Mechanisms of the Inhibited Complexes
title Inhibitor Design Strategy for Myostatin: Dynamics and Interaction Networks Define the Affinity and Release Mechanisms of the Inhibited Complexes
title_full Inhibitor Design Strategy for Myostatin: Dynamics and Interaction Networks Define the Affinity and Release Mechanisms of the Inhibited Complexes
title_fullStr Inhibitor Design Strategy for Myostatin: Dynamics and Interaction Networks Define the Affinity and Release Mechanisms of the Inhibited Complexes
title_full_unstemmed Inhibitor Design Strategy for Myostatin: Dynamics and Interaction Networks Define the Affinity and Release Mechanisms of the Inhibited Complexes
title_short Inhibitor Design Strategy for Myostatin: Dynamics and Interaction Networks Define the Affinity and Release Mechanisms of the Inhibited Complexes
title_sort inhibitor design strategy for myostatin: dynamics and interaction networks define the affinity and release mechanisms of the inhibited complexes
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10420283/
https://www.ncbi.nlm.nih.gov/pubmed/37570625
http://dx.doi.org/10.3390/molecules28155655
work_keys_str_mv AT nagyfazekasdora inhibitordesignstrategyformyostatindynamicsandinteractionnetworksdefinetheaffinityandreleasemechanismsoftheinhibitedcomplexes
AT fazekaszsolt inhibitordesignstrategyformyostatindynamicsandinteractionnetworksdefinetheaffinityandreleasemechanismsoftheinhibitedcomplexes
AT taricskanora inhibitordesignstrategyformyostatindynamicsandinteractionnetworksdefinetheaffinityandreleasemechanismsoftheinhibitedcomplexes
AT stranerpal inhibitordesignstrategyformyostatindynamicsandinteractionnetworksdefinetheaffinityandreleasemechanismsoftheinhibitedcomplexes
AT karancsinemenyharddora inhibitordesignstrategyformyostatindynamicsandinteractionnetworksdefinetheaffinityandreleasemechanismsoftheinhibitedcomplexes
AT perczelandras inhibitordesignstrategyformyostatindynamicsandinteractionnetworksdefinetheaffinityandreleasemechanismsoftheinhibitedcomplexes